The Tie Is Broken: Stroke Risk with Low CHA2DS2-VASc in Nonvalvular AF

Patients with nonvalvular atrial fibrillation and a low CHA₂DS₂-VASc score are unlikely to benefit from anticoagulation.

Whether patients with atrial fibrillation (AF) and a very low CHA₂DS₂-VASc score benefit from anticoagulation is unclear. The Danish National Registry study is the third large registry analysis of the topic published this year (NEJM JW Cardiol Mar 2015 and J Am Coll Cardiol 2015; 65:225 and 233; NEJM JW Cardiol May 2015 and J Am Coll Cardiol 2015; 65:635 and 643). In this registry, 39,400 patients were discharged with a diagnosis of nonvalvular AF and a CHA₂DS₂-VASc score of 0 or 1 — 5353 on aspirin, 10,475 on warfarin, and 23,572 on neither.

Mean follow-up was 5.9 years. In male patients with a CHA₂DS₂-VASc score of 0 and female patients without any additional CHA₂DS₂-VASc points, the ischemic stroke rate per 100 person-years was 0.43 and t…

Reviewing Author

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

Mark S. Link, MD

Disclosures

Editorial BoardsCirculation; UpToDate

The Tie Is Broken: Stroke Risk with Low CHA₂DS₂-VASc in Nonvalvular AF

Topics

Reviewing Author